MX347038B - Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas. - Google Patents

Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas.

Info

Publication number
MX347038B
MX347038B MX2013009715A MX2013009715A MX347038B MX 347038 B MX347038 B MX 347038B MX 2013009715 A MX2013009715 A MX 2013009715A MX 2013009715 A MX2013009715 A MX 2013009715A MX 347038 B MX347038 B MX 347038B
Authority
MX
Mexico
Prior art keywords
methods
preparation
membrane proteins
water soluble
soluble membrane
Prior art date
Application number
MX2013009715A
Other languages
English (en)
Other versions
MX2013009715A (es
Inventor
Shuguang Zhang
Alexander Rich
Karolina Corin
Lotta T Tegler
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2013009715A publication Critical patent/MX2013009715A/es
Publication of MX347038B publication Critical patent/MX347038B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a una variante soluble en agua de un receptor acoplado de proteína G (GPCR), caracterizada porque en dicha variante los residuos hidrofóbicos del dominio ahelicoidal 7-transmembránico, que son leucina (L), isoleucina (I), valina (V) y fenilalanina (F) en la superficie hidrofílica en las posiciones a-helicoidales b, c y f, pero no en las posiciones a-helicoidales a, d, e y g de la GPCR, son reemplazados por glutamina (Q), treonina (T) treonina (T) , tirosina (Y), respectivamente; de manera opcional además comprende sustituciones conservativas en otras partes de la variante.
MX2013009715A 2011-02-23 2012-02-23 Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas. MX347038B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23
PCT/US2012/026353 WO2012116203A1 (en) 2011-02-23 2012-02-23 Water soluble membrane proteins and methods for the preparation and use thereof

Publications (2)

Publication Number Publication Date
MX2013009715A MX2013009715A (es) 2014-02-28
MX347038B true MX347038B (es) 2017-04-10

Family

ID=46721234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009715A MX347038B (es) 2011-02-23 2012-02-23 Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas.

Country Status (14)

Country Link
US (4) US8637452B2 (es)
EP (1) EP2709647B1 (es)
JP (1) JP6263773B2 (es)
KR (1) KR101963914B1 (es)
CN (2) CN103458915A (es)
AU (3) AU2012220558A1 (es)
BR (1) BR112013020969A2 (es)
CA (1) CA2827187C (es)
CL (1) CL2013002419A1 (es)
EA (1) EA201391041A1 (es)
IL (2) IL227886A0 (es)
MX (1) MX347038B (es)
SG (2) SG192646A1 (es)
WO (1) WO2012116203A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
SG11201507370TA (en) 2013-03-14 2015-10-29 Massachusetts Inst Technology Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
US9670264B2 (en) * 2013-04-25 2017-06-06 The Trustees Of The University Of Pennsylvania Water soluble G-protein coupled receptor
US10809222B2 (en) 2013-04-25 2020-10-20 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015148820A1 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
GB2527286A (en) 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
CN104198689A (zh) * 2014-08-25 2014-12-10 李洁 一种检测g-蛋白耦联受体对缩血管物质反应的方法
CN113929766A (zh) * 2015-02-18 2022-01-14 麻省理工学院 水溶性跨膜蛋白及其制备和使用方法
CN104946674B (zh) * 2015-06-17 2018-05-01 山东大学 一种腺苷三磷酸/双磷酸酶及其编码基因与应用
CN106749602A (zh) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 一种助表达序列及其在无细胞表达adcy2蛋白中的应用
US11293923B2 (en) 2017-09-01 2022-04-05 Massachusetts Institute Of Technology S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof
US11414456B2 (en) 2017-12-11 2022-08-16 Astellas Pharma Inc. Cell penetrating peptide
CN108245686B (zh) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 人grk5基因的用途
US11555060B2 (en) * 2020-03-25 2023-01-17 Avalon GloboCare Corp. QTY FC fusion water soluble receptor proteins
WO2021202186A2 (en) 2020-03-31 2021-10-07 Massachusetts Institute Of Technology Qty fc fusion receptor proteins
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
JPH09278793A (ja) * 1996-04-10 1997-10-28 Kinichiro Miura ポリペプチド
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP1159289A1 (en) * 1999-03-11 2001-12-05 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
CA2517848A1 (en) 2003-01-21 2004-08-05 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006026355A2 (en) 2004-08-25 2006-03-09 Janssen Pharmaceutica N.V. Relaxin-chimeric polypeptides and their preparation and use
EP1885746B1 (en) * 2005-02-08 2012-01-11 Research Development Foundation Compositions related to soluble g-protein coupled receptors (sgpcrs)
BRPI0502759B1 (pt) * 2005-06-30 2014-02-25 óleo lubrificante e composição lubrificante para uma máquina de refrigeração
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
UA97953C2 (uk) 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
CA2681415C (en) 2007-03-22 2020-11-03 Heptares Therapeutics Limited Mutant g-protein coupled receptors and methods for selecting them
WO2008143910A2 (en) * 2007-05-18 2008-11-27 University Of Massachusetts A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
WO2008068534A2 (en) 2008-03-05 2008-06-12 Heptares Therapeutics Limited Crystal structure of a betal -adremergi c receptor and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
DK2531492T3 (en) 2010-02-05 2016-07-04 Heptares Therapeutics Ltd 1,2,4-triazin-4-amine derivatives
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
US20140031525A1 (en) 2011-01-21 2014-01-30 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof

Also Published As

Publication number Publication date
EA201391041A1 (ru) 2014-04-30
MX2013009715A (es) 2014-02-28
AU2016201914A1 (en) 2016-04-21
CA2827187C (en) 2019-01-08
JP6263773B2 (ja) 2018-01-24
US8637452B2 (en) 2014-01-28
CN108752461A (zh) 2018-11-06
JP2014508763A (ja) 2014-04-10
US20180312562A1 (en) 2018-11-01
US9309302B2 (en) 2016-04-12
SG192646A1 (en) 2013-09-30
AU2012220558A1 (en) 2013-08-22
BR112013020969A2 (pt) 2018-07-10
CA2827187A1 (en) 2012-08-30
EP2709647A1 (en) 2014-03-26
US20160264640A1 (en) 2016-09-15
AU2017261525A1 (en) 2017-12-07
IL261151A (en) 2018-10-31
IL227886A0 (en) 2013-09-30
EP2709647B1 (en) 2019-08-07
US20140243277A1 (en) 2014-08-28
EP2709647A4 (en) 2015-01-21
US10035837B2 (en) 2018-07-31
WO2012116203A1 (en) 2012-08-30
CN103458915A (zh) 2013-12-18
KR101963914B1 (ko) 2019-03-29
KR20140027117A (ko) 2014-03-06
CL2013002419A1 (es) 2014-06-06
US20120252719A1 (en) 2012-10-04
SG10201701547VA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX347038B (es) Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
AU340311S (en) Toy
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
AU341113S (en) Pipe coupling segment
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
AU341185S (en) Pipe coupling segment
AU341110S (en) Pipe coupling segment
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
AU341180S (en) Pipe coupling segment
AU341178S (en) Pipe coupling segment
AU341112S (en) Pipe coupling segment
AU341183S (en) Pipe coupling segment
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
AU341181S (en) Pipe coupling segment
MY161601A (en) Films and compositions comprising the same
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
WO2012022496A3 (en) Method for killing tumor stem cells
GT201300307A (es) "derivados de pirazol útiles como inhibidores de aldosterona sintasa"
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
WO2015149085A8 (en) Water-soluble trans-membrane proteins and methods for the preparation and use thereof
IN2012DN03290A (es)

Legal Events

Date Code Title Description
FG Grant or registration